Akari Therapeutics, Plc
AKTX
$1.12
-$0.03-2.61%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Net Income | -8.17% | -97.75% | -116.37% | -103.56% | -43.25% |
| Total Depreciation and Amortization | -93.75% | 250.00% | 250.00% | 275.00% | 310.26% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 631.02% | 112.33% | 101.57% | 105.83% | 96.65% |
| Change in Net Operating Assets | 325.33% | 855.08% | 566.02% | 35.84% | 764.49% |
| Cash from Operations | 31.66% | 23.61% | 7.06% | 9.50% | 26.90% |
| Capital Expenditure | -- | -- | -- | -- | -- |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -- | -- | -- |
| Cash from Investing | -- | -- | -- | -- | -- |
| Total Debt Issued | -- | -- | 102,700.00% | -- | -- |
| Total Debt Repaid | -901.86% | -- | -- | -- | -- |
| Issuance of Common Stock | 132.41% | 70.25% | 23.86% | -24.86% | -65.67% |
| Repurchase of Common Stock | -13,500.00% | -13,500.00% | -13,500.00% | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | 118.09% | 56.52% | 23.96% | -22.10% | -67.01% |
| Foreign Exchange rate Adjustments | -50.00% | -157.14% | -96.68% | -103.32% | -96.70% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 112.97% | 87.39% | 58.37% | -209.69% | -99.83% |